Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811681 | 1.00 | MAPK1 (1.00) | MAPK1KMT2ARAB9ACA1CA2 | |
| SCHEMBL8935897 | 0.82 | MAPK1 (0.70) | MAPK1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL14948534 | 0.82 | MAPK1 (0.69) | MAPK1KMT2ARAB9ACA9TSHR | |
| SCHEMBL10731151 | 0.80 | MAPK1 (0.65) | MAPK1KMT2ARAB9ATSHRPOLB | |
| SCHEMBL23144183 | 0.80 | MAPK1 (0.67) | MAPK1KMT2ARAB9ACYP3A4CYP2D6 | |
| SCHEMBL9575717 | 0.80 | MAPK1 (0.67) | MAPK1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL4784138 | 0.80 | MAPK1 (0.66) | MAPK1KMT2ARAB9ACA9POLB | |
| SCHEMBL10052099 | 0.79 | MAPK1 (0.65) | MAPK1KMT2ARAB9ATSHRALDH1A1 | |
| SCHEMBL8939993 | 0.79 | ALDH1A1 (0.64) | MAPK1KMT2ARAB9ACA9ALDH1A1 | |
| SCHEMBL772374 | 0.78 | KMT2A (0.69) | MAPK1KMT2ARAB9ACA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115003299-A | Methods and compounds for restoring function of mutant p53 | 皮姆维制药公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4034104-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021061643-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061643-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-5531978-A | CHELATE COMPOUNDS, IMAGING | NYCOMED IMAGING AS (NO) | 1996-07-02 | — | — | US | disclosed |
| US-5419893-A | Aminopolycarboxylic acids and derivatives thereof for magnetic resonance imaging | NYCOMED IMAGING AS (NO) | 1995-05-30 | — | — | US | disclosed |
| US-5198208-A | Chelate compounds for diagnosis by magnetic resonance imaging, ultrasound or radiation therapy | NYCOMED IMAGING AS (NO) | 1993-03-30 | — | — | US | disclosed |
| EP-0466200-A1 | Aminocarboxylic acids and derivatives thereof | NYCOMED IMAGING AS (NO) | 1992-01-15 | — | — | EP | disclosed |
| WO-1989000557-A1 | AMINOPOLYCARBOXYLIC ACIDS AND DERIVATIVES THEREOF | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1989-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | MAPK1 2448/4885KMT2A 2966/4885RAB9A 2402/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | MAPK1 2448/4885KMT2A 2966/4885RAB9A 2402/4885 |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | MAPK1 2448/4885KMT2A 2966/4885RAB9A 2402/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | MAPK1 2448/4885KMT2A 2966/4885RAB9A 2402/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | MAPK1 646/4885KMT2A 1704/4885RAB9A 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.